University of Minnesota

Allaysis, LLC

Lundbeck Pharmaceuticals LLC

Other

James C Cloyd

Linda Krach

Rob Tuohy

John Schrogie

Robert L Kriel

Adolfo L Gomez

Stephen John Tucker

Stephen D Collins

Ronald A Siegel

Mamta Kapoor

Angela Birnbaum

Ilo Leppik

Gunda I Georg

Narsihmulu Cheryala

Tate Winter

An intravenous baclofen solution is disclosed, along with methods of dosing and treatment therewith.

Intravenous baclofen formulations and treatment methods

The present invention is directed to compositions comprising topiramate and a sulfoalkyl ether cyclodextrin, and methods of making and using the same.

Topiramate compositions and methods of making and using the same

Certain embodiments of the invention provide a formulation suitable for nasal administration comprising water, a prodrug of a therapeutic agent, and an enzyme that is suitable for intranasal conversion of the prodrug to the therapeutic agent, as well as methods of use thereof.

Therapeutic compounds and formulations for intranasal delivery

Music education set of cards

The present invention relates to a new drug delivery strategy based on prodrug conversion, in which a water-soluble prodrug and its converting enzyme are co-delivered and at a point of administration such as the nasal or buccal mucosa. Enzymatic conversion of the prodrug produces drug in concentrations exceeding the drug's thermodynamic solubility, or saturation level. The supersaturated drug crosses the mucosal membrane quickly, as a result of its high thermodynamic activity, prior to crystallization. This strategy is particularly useful when fast action is required, for example in preventing or responding rapidly to Status Epilepticus (SE) or other central nervous system conditions such as migraine.

Drug delivery method

The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.

Parenteral carbamazepine formulation

Growing community of inventors

Edina, MN, United States of America

James C Cloyd